Why the study?
Clopidogrel resistance in acute ischemic stroke can lead to recurrence and bleeding, motivating the identification of associated factors and development of a predictive nomogram.
What are the clinical predictors of clopidogrel resistance in acute ischemic stroke patients, and can a nomogram accurately predict this risk?
What are the clinical predictors of clopidogrel resistance in acute ischemic stroke patients, and can a nomogram accurately predict this risk?
A novel diagnostic nomogram incorporating clinical factors like unstable carotid plaque, proton pump inhibitor use, and apolipoprotein levels can effectively predict clopidogrel resistance in acute ischemic stroke patients.
Nomogram may aid CR risk stratification in AIS; leaves open prospective validation before clinical use.
BACKGROUND: Clopidogrel plays an important role in the treatment of acute ischemic strokes (AIS) through antiplatelet activity. However, some patients have clopidogrel resistance (CR), which could lead to stroke recurrence and bleeding. This study aimed to explore associated factors of CR and establish a diagnostic nomogram for predicting the probability of CR in AIS patients. METHODS: This retrospective study involved 692 AIS patients from the Second Affiliated Hospital of Guangzhou Medical University, treated with clopidogrel (75 mg/day for 5 ± 2 days) after admission. Platelet reactivity was evaluated using thromboelastography to measure the ADP-induced platelet inhibition ratio (ADP-PIR). Patients were classified into CR (ADP-PIR < 30%) and non-clopidogrel resistance (NCR) groups. Group comparison, followed by least absolute shrinkage and selection operator (LASSO) regression and multivariable logistic regression, was used to identify key predictors of CR. A diagnostic nomogram was developed and its performance was validated using bootstrap resampling. RESULTS: 16.76% of 692 patients experienced CR after AIS. Beta blocker use (OR: 0.47, 95% CI: 0.22-1.03, P = 0.058) and apolipoprotein A1 (OR: 0.17, 95% CI: 0.07-0.46, P < 0.001) were identified as protective factors, while unstable carotid plaque (OR: 10.65, 95% CI: 4.18-27.13, P < 0.001), high apolipoprotein B levels (OR: 2.35, 95% CI: 1.23-4.51, P = 0.01), and proton pump inhibitors use (OR: 2.09, 95% CI: 1.32-3.31, P = 0.002) were risk factors. Our nomogram effectively validated these factors, showing strong discrimination and clinical utility in diagnosing CR probability. CONCLUSIONS: We identified several significant CR predictors and further developed a diagnostic nomogram of CR to help clinicians choose antiplatelet drugs. TRIAL RETROSPECTIVELY REGISTRATION: Trial Retrospectively registration = ChiCTR2300073944. DATA: 2023-7-25. The present study was approved by the Ethics Committee of the Second Affiliated Hospital of Guangzhou Medical University.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: